Heron Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
22.9%projected annual EPS growth
Analyst Coverage
1analyst covering
FY Revenue (est.)
$165.7Mnext fiscal year
FY EPS (est.)
-$0.09next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 5 Nov 2026 |
| Q4 and Full-Year 2026 Earnings Release | 25 Feb 2027 |
Monitoring Framework
Key Performance Indicators
Acute Care Franchise Net Revenue Quarterly13.6M
Oncology Supportive Care Franchise Net Revenue Quarterly21.1M
ZYNRELEF Net Revenue Quarterly10.2M
APONVIE Net Revenue Quarterly3.4M
CINVANTI Net Revenue Quarterly20.5M
Total Net Product Sales Guidance Annually34.7MTarget: 173000000 to 183000000
Adjusted EBITDA Guidance Annually-727KTarget: 10000000 to 20000000
Watch Items
- CINVANTI Patent Litigation and Generic CompetitionTrigger: U.S. District Court in Delaware ruling declaring certain CINVANTI patent claims invalidAction: Monitor legal appeals, potential generic market entry timelines, and the impact on the REIGNITE commercial program designed to return CINVANTI to steady growth.
- Acute Care Sales Force ExpansionTrigger: Planned commercial sales force expansion scheduled for Q3 2026Action: Track recruitment progress, onboarding timelines, and subsequent demand unit growth for ZYNRELEF and APONVIE in late 2026.
- SUSTOL Product Wind-DownTrigger: Complete wind-down of SUSTOL commercialization by the end of 2026Action: Verify the final transition of oncology supportive care resources exclusively toward CINVANTI and the REIGNITE program.
Research as of 20 Jun 2026